According to a Lancet study, ariptadil does not enhance clinical outcomes in COVID-19 patients who have acute hypoxaemic respiratory failure.

Published Date: 23 Jun 2023

USA: Patients with acute hypoxemic respiratory disease associated with COVID-19 did not respond better to intravenous aviptadil up to day 90.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers find distinct cell receptors with the potential for new treatments.

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Too Many Chest CTs for Incidental Lung Nodules?

5.

Global warming could be driving up women's cancer risk, find researchers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot